A Pan India Registry to Understand the Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies

Abbott Healthcare Pvt Ltd0 个研究点目标入组 255 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•1. Patients with age >= 18 years and <= 65 years atenrollment
•2. Patients who provide written consent/patient authorization form (PAF) for
•participation in thestudy
•3. Patients diagnosed with CKD stages 2, 3A, 3B, or 4 (as per CKD Clinical Practice
•Recommendations for Primary Care Physicians and Healthcare Providers27) along
•with elevated levels of SUA ( > 7 mg/dL [420 Î¼M] in men and > 6 mg/dL [360 Î¼M] in

•Patients meeting any of the following criteria will not be included in the study:
•1. Patients with reduced life expectancy (e.g., less than 6 months) due to recent diagnosis of advanced cancer (e.g., within last 2 years) and other life-threatening conditions
•2. Patients with a mental condition rendering them unable to understand the nature, scope, and possible consequences of the study
•3. Patients actively enrolled in another interventional study
•4. Patients who are unwilling to adhere to protocol requirements
•5. Pregnant and lactating females
•6. Patients with comprehension disorder(s) making it impossible to understand the protocol
•7. Patients with chronic disease requiring long

发起方